{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,13]],"date-time":"2026-02-13T09:31:24Z","timestamp":1770975084749,"version":"3.50.1"},"reference-count":108,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100005026","name":"Stichting Tegen Kanker","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100005026","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["cancertreatmentreviews.com","clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cancer Treatment Reviews"],"published-print":{"date-parts":[[2024,7]]},"DOI":"10.1016\/j.ctrv.2024.102752","type":"journal-article","created":{"date-parts":[[2024,5,12]],"date-time":"2024-05-12T14:04:23Z","timestamp":1715522663000},"page":"102752","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"special_numbering":"C","title":["Non-operative management after immune checkpoint inhibitors for early-stage, dMMR\/MSI-H gastrointestinal cancers"],"prefix":"10.1016","volume":"128","author":[{"given":"Roberta","family":"Fazio","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alessandro","family":"Audisio","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Valentina","family":"Dapr\u00e0","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chiara","family":"Conti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nada","family":"Benhima","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fatima-Zahara","family":"Abbassi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Irene","family":"Assaf","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alain","family":"Hendlisz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Francesco","family":"Sclafani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"10","key":"10.1016\/j.ctrv.2024.102752_b0005","doi-asserted-by":"crossref","first-page":"1291","DOI":"10.1016\/j.annonc.2020.06.022","article-title":"Localised colon cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"31","author":"Argil\u00e9s","year":"2020","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ctrv.2024.102752_b0010","doi-asserted-by":"crossref","unstructured":"Glynne-Jones R, Wyrwicz L, Tiret E, Brown G, R\u00f6del C, Cervantes A, et al. Rectal cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2017 Jul;28:iv22\u201340.","DOI":"10.1093\/annonc\/mdx224"},{"issue":"10","key":"10.1016\/j.ctrv.2024.102752_b0015","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.1016\/j.annonc.2022.07.004","article-title":"Gastric cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up","volume":"33","author":"Lordick","year":"2022","journal-title":"Ann Oncol"},{"issue":"10","key":"10.1016\/j.ctrv.2024.102752_b0020","doi-asserted-by":"crossref","first-page":"992","DOI":"10.1016\/j.annonc.2022.07.003","article-title":"Oesophageal cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up","volume":"33","author":"Obermannov\u00e1","year":"2022","journal-title":"Ann Oncol"},{"issue":"3","key":"10.1016\/j.ctrv.2024.102752_b0025","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1007\/BF02586980","article-title":"Combined therapy for cancer of the anal canal: A preliminary report","volume":"17","author":"Nigro","year":"1974","journal-title":"Dis Colon Rectum"},{"issue":"2","key":"10.1016\/j.ctrv.2024.102752_b0030","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1007\/BF02604287","article-title":"Combined therapy for cancer of the anal canal","volume":"24","author":"Nigro","year":"1981","journal-title":"Dis Colon Rectum"},{"issue":"4","key":"10.1016\/j.ctrv.2024.102752_b0035","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1097\/01.sla.0000141194.27992.32","article-title":"Operative versus nonoperative treatment for stage 0 distal rectal cancer following chemoradiation therapy: long-term results","volume":"240","author":"Habr-Gama","year":"2004","journal-title":"Ann Surg"},{"issue":"10139","key":"10.1016\/j.ctrv.2024.102752_b0040","doi-asserted-by":"crossref","first-page":"2537","DOI":"10.1016\/S0140-6736(18)31078-X","article-title":"Long-term outcomes of clinical complete responders after neoadjuvant treatment for rectal cancer in the International Watch & Wait Database (IWWD): an international multicentre registry study","volume":"391","author":"Van Der Valk","year":"2018","journal-title":"Lancet"},{"key":"10.1016\/j.ctrv.2024.102752_b0045","unstructured":"Benson AB et al. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines\u00ae), Rectal cancer, version 6.2023 \u2014 November 16, 2023. Accessed January 21, 2024."},{"issue":"15","key":"10.1016\/j.ctrv.2024.102752_b0050","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1186\/s12885-015-1632-z","volume":"23","author":"Smith","year":"2015","journal-title":"BMC Cancer"},{"key":"10.1016\/j.ctrv.2024.102752_b0055","doi-asserted-by":"crossref","DOI":"10.1016\/j.annonc.2023.10.076","article-title":"LBA75 Neoadjuvant chemoradiotherapy followed by surgery versus active surveillance for oesophageal cancer (SANO-trial): A phase-III stepped-wedge cluster randomised trial","volume":"34","author":"Van Der Wilk","year":"2023","journal-title":"Ann Oncol"},{"issue":"9","key":"10.1016\/j.ctrv.2024.102752_b0060","doi-asserted-by":"crossref","first-page":"e403","DOI":"10.1016\/S1470-2045(12)70236-X","article-title":"Anterior resection syndrome","volume":"13","author":"Bryant","year":"2012","journal-title":"Lancet Oncol"},{"issue":"8","key":"10.1016\/j.ctrv.2024.102752_b0065","doi-asserted-by":"crossref","first-page":"1095","DOI":"10.1007\/s00384-012-1413-y","article-title":"Early complications after stoma formation: a prospective cohort study in 100 patients with 1-year follow-up","volume":"27","author":"Formijne Jonkers","year":"2012","journal-title":"Int J Colorectal Dis"},{"key":"10.1016\/j.ctrv.2024.102752_b0070","article-title":"Quality of life after sphincter preservation surgery or abdominoperineal resection for low rectal cancer (ASPIRE): A long-term prospective, multicentre, cohort study","volume":"6","author":"Kang","year":"2021","journal-title":"Lancet Reg Health - West Pac"},{"issue":"6","key":"10.1016\/j.ctrv.2024.102752_b0075","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1016\/S1470-2045(13)70086-X","article-title":"Mitomycin or cisplatin chemoradiation with or without maintenance chemotherapy for treatment of squamous-cell carcinoma of the anus (ACT II): a randomised, phase 3, open-label, 2\u00d72 factorial trial","volume":"14","author":"James","year":"2013","journal-title":"Lancet Oncol"},{"issue":"5","key":"10.1016\/j.ctrv.2024.102752_b0080","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1111\/ans.15552","article-title":"Impact of temporary ileostomy on long-term quality of life and bowel function: a systematic review and meta-analysis","volume":"90","author":"Keane","year":"2020","journal-title":"ANZ J Surg"},{"issue":"8","key":"10.1016\/j.ctrv.2024.102752_b0085","doi-asserted-by":"crossref","first-page":"1985","DOI":"10.1016\/j.ejso.2021.05.034","article-title":"Postoperative outcomes after laparoscopic or open gastrectomy. A national cohort study of 10,343 patients","volume":"47","author":"Challine","year":"2021","journal-title":"Eur J Surg Oncol"},{"issue":"2","key":"10.1016\/j.ctrv.2024.102752_b0090","article-title":"Improved morbidity, mortality, and cost with minimally invasive colon resection compared to open surgery","volume":"26","author":"Hakmi","year":"2022","journal-title":"JSLS J Soc Laparosc Robot Surg"},{"issue":"3","key":"10.1016\/j.ctrv.2024.102752_b0095","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1007\/s41999-023-00750-9","article-title":"Health-related quality-of-life trajectories during\/after surgery and adjuvant chemotherapy in patients with colon cancer","volume":"14","author":"Scheepers","year":"2023","journal-title":"Eur Geriatr Med"},{"issue":"10184","key":"10.1016\/j.ctrv.2024.102752_b0100","doi-asserted-by":"crossref","first-page":"1948","DOI":"10.1016\/S0140-6736(18)32557-1","volume":"393","author":"Al-Batran","year":"2019","journal-title":"Lancet"},{"issue":"22","key":"10.1016\/j.ctrv.2024.102752_b0105","doi-asserted-by":"crossref","first-page":"2074","DOI":"10.1056\/NEJMoa1112088","article-title":"Preoperative chemoradiotherapy for esophageal or junctional cancer","volume":"366","author":"Van Hagen","year":"2012","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.ctrv.2024.102752_b0110","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/S1470-2045(20)30555-6","article-title":"Short-course radiotherapy followed by chemotherapy before total mesorectal excision (TME) versus preoperative chemoradiotherapy, TME, and optional adjuvant chemotherapy in locally advanced rectal cancer (RAPIDO): a randomised, open-label, phase 3 trial","volume":"22","author":"Bahadoer","year":"2021","journal-title":"Lancet Oncol"},{"issue":"5","key":"10.1016\/j.ctrv.2024.102752_b0115","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1016\/S1470-2045(21)00079-6","article-title":"Neoadjuvant chemotherapy with FOLFIRINOX and preoperative chemoradiotherapy for patients with locally advanced rectal cancer (UNICANCER-PRODIGE 23): a multicentre, randomised, open-label, phase 3 trial","volume":"22","author":"Conroy","year":"2021","journal-title":"Lancet Oncol"},{"issue":"8","key":"10.1016\/j.ctrv.2024.102752_b0120","doi-asserted-by":"crossref","first-page":"1541","DOI":"10.1200\/JCO.22.00046","article-title":"Preoperative chemotherapy for operable colon cancer: mature results of an international randomized controlled trial","volume":"41","author":"Morton","year":"2023","journal-title":"J Clin Oncol"},{"issue":"16_suppl","key":"10.1016\/j.ctrv.2024.102752_b0125","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2022.40.16_suppl.3500","article-title":"Perioperative chemotherapy with mFOLFOX6 or CAPOX for patients with locally advanced colon cancer (OPTICAL): A multicenter, randomized, phase 3 trial","volume":"40","author":"Hu","year":"2022","journal-title":"J Clin Oncol"},{"issue":"6349","key":"10.1016\/j.ctrv.2024.102752_b0130","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1126\/science.aan6733","article-title":"Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade","volume":"357","author":"Le","year":"2017","journal-title":"Science"},{"issue":"13","key":"10.1016\/j.ctrv.2024.102752_b0135","doi-asserted-by":"crossref","first-page":"3753","DOI":"10.1158\/1078-0432.CCR-18-4070","article-title":"FDA approval summary: pembrolizumab for the treatment of microsatellite instability-high solid tumors","volume":"25","author":"Marcus","year":"2019","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ctrv.2024.102752_b0140","unstructured":"EMA Recommends Extension of Indications for Pembrolizumab to MSI-H or dMMR Cancers and to Metastatic Cervical Cancer with PD-L1 CPS \u22651. https:\/\/www.esmo.org\/oncology-news\/ema-recommends-extension-of-indications-for-pembrolizumab-to-msi-h-or-dmmr-cancers-and-to-metastatic-cervical-cancer-with-pd-l1-cps-1."},{"key":"10.1016\/j.ctrv.2024.102752_b0145","doi-asserted-by":"crossref","first-page":"S1271","DOI":"10.1016\/j.annonc.2023.10.024","article-title":"LBA32 Pembrolizumab versus chemotherapy in microsatellite instability-high (MSI-H)\/mismatch repair-deficient (dMMR) metastatic colorectal cancer (mCRC): 5-year follow-up of the randomized phase III KEYNOTE-177 study","volume":"34","author":"Shiu","year":"2023","journal-title":"Ann Oncol"},{"issue":"10","key":"10.1016\/j.ctrv.2024.102752_b0150","doi-asserted-by":"crossref","first-page":"1356","DOI":"10.1001\/jamaoncol.2023.2761","article-title":"Avelumab vs standard second-line chemotherapy in patients with metastatic colorectal cancer and microsatellite instability: A randomized clinical trial","volume":"9","author":"Ta\u00efeb","year":"2023","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.ctrv.2024.102752_b0155","doi-asserted-by":"crossref","unstructured":"Andre T, Elez E, Van Cutsem E, Jensen LH, Bennouna J, et al. Nivolumab (NIVO) plus ipilimumab (IPI) vs chemotherapy (chemo) as first-line (1L) treatment for microsatellite instability-high\/mismatch repair-deficient (MSI-H\/dMMR) metastatic colorectal cancer (mCRC): First results of the CheckMate 8HW study. J Clin Oncol 42, 2024 (suppl 3; abstr LBA768).","DOI":"10.1200\/JCO.2024.42.3_suppl.LBA768"},{"issue":"4_suppl","key":"10.1016\/j.ctrv.2024.102752_b0160","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2018.36.4_suppl.554","article-title":"Nivolumab in patients with DNA mismatch repair-deficient\/microsatellite instability-high (dMMR\/MSI-H) metastatic colorectal cancer (mCRC): Long-term survival according to prior line of treatment from CheckMate-142","volume":"36","author":"Overman","year":"2018","journal-title":"J Clin Oncol"},{"issue":"10","key":"10.1016\/j.ctrv.2024.102752_b0165","doi-asserted-by":"crossref","first-page":"1052","DOI":"10.1016\/j.annonc.2022.06.008","article-title":"Nivolumab plus low-dose ipilimumab in previously treated patients with microsatellite instability-high\/mismatch repair-deficient metastatic colorectal cancer: 4-year follow-up from CheckMate 142","volume":"33","author":"Andr\u00e9","year":"2022","journal-title":"Ann Oncol"},{"issue":"186","key":"10.1016\/j.ctrv.2024.102752_b0170","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/j.ejca.2023.02.016","article-title":"Pembrolizumab for previously treated, microsatellite instability-high\/mismatch repair-deficient advanced colorectal cancer: final analysis of KEYNOTE-164","volume":"1990","author":"Le","year":"2023","journal-title":"Eur J Cancer Oxf Engl"},{"issue":"7903","key":"10.1016\/j.ctrv.2024.102752_b0175","doi-asserted-by":"crossref","first-page":"942","DOI":"10.1038\/s41586-022-04508-4","article-title":"Nivolumab plus chemotherapy or ipilimumab in gastro-oesophageal cancer","volume":"603","author":"Shitara","year":"2022","journal-title":"Nature"},{"issue":"10","key":"10.1016\/j.ctrv.2024.102752_b0180","doi-asserted-by":"crossref","first-page":"1456","DOI":"10.1001\/jamaoncol.2022.3707","article-title":"Association of PD-L1 expression and other variables with benefit from immune checkpoint inhibition in advanced gastroesophageal cancer: systematic review and meta-analysis of 17 phase 3 randomized clinical trials","volume":"8","author":"Yoon","year":"2022","journal-title":"JAMA Oncol"},{"issue":"5","key":"10.1016\/j.ctrv.2024.102752_b0185","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1016\/S1470-2045(22)00197-8","article-title":"Pembrolizumab versus chemotherapy for microsatellite instability-high or mismatch repair-deficient metastatic colorectal cancer (KEYNOTE-177): final analysis of a randomised, open-label, phase 3 study","volume":"23","author":"Diaz","year":"2022","journal-title":"Lancet Oncol"},{"issue":"6","key":"10.1016\/j.ctrv.2024.102752_b0190","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1001\/jamaoncol.2021.0275","article-title":"Assessment of pembrolizumab therapy for the treatment of microsatellite instability-high gastric or gastroesophageal junction cancer among patients in the KEYNOTE-059, KEYNOTE-061, and KEYNOTE-062 clinical trials","volume":"7","author":"Chao","year":"2021","journal-title":"JAMA Oncol"},{"issue":"4","key":"10.1016\/j.ctrv.2024.102752_b0195","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1038\/s41591-020-0829-0","article-title":"Learning from clinical trials of neoadjuvant checkpoint blockade","volume":"26","author":"Versluis","year":"2020","journal-title":"Nat Med"},{"issue":"12","key":"10.1016\/j.ctrv.2024.102752_b0200","doi-asserted-by":"crossref","first-page":"1417","DOI":"10.1093\/bjs\/znab342","article-title":"Neoadjuvant immunotherapy in primary and metastatic colorectal cancer","volume":"108","author":"Kanani","year":"2021","journal-title":"Br J Surg"},{"issue":"9","key":"10.1016\/j.ctrv.2024.102752_b0205","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1056\/NEJMoa2211437","article-title":"Neoadjuvant-adjuvant or adjuvant-only pembrolizumab in advanced melanoma","volume":"388","author":"Patel","year":"2023","journal-title":"N Engl J Med"},{"issue":"20","key":"10.1016\/j.ctrv.2024.102752_b0210","doi-asserted-by":"crossref","first-page":"3219","DOI":"10.1200\/JCO.2009.27.1825","article-title":"Defective mismatch repair as a predictive marker for lack of efficacy of fluorouracil-based adjuvant therapy in colon cancer","volume":"28","author":"Sargent","year":"2010","journal-title":"J Clin Oncol"},{"issue":"13","key":"10.1016\/j.ctrv.2024.102752_b0215","doi-asserted-by":"crossref","first-page":"3271","DOI":"10.1158\/1078-0432.CCR-19-3728","article-title":"Mismatch repair-deficient rectal cancer and resistance to neoadjuvant chemotherapy","volume":"26","author":"Cercek","year":"2020","journal-title":"Clin Cancer Res"},{"issue":"35","key":"10.1016\/j.ctrv.2024.102752_b0220","doi-asserted-by":"crossref","first-page":"3392","DOI":"10.1200\/JCO.19.01124","article-title":"Individual patient data meta-analysis of the value of microsatellite instability as a biomarker in gastric cancer","volume":"37","author":"Pietrantonio","year":"2019","journal-title":"J Clin Oncol"},{"issue":"4","key":"10.1016\/j.ctrv.2024.102752_b0225","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1200\/JCO.23.00975","article-title":"Perioperative atezolizumab plus fluorouracil, leucovorin, oxaliplatin, and docetaxel for resectable esophagogastric cancer: interim results from the randomized, multicenter, phase II\/III DANTE\/IKF-s633 trial","volume":"42","author":"Lorenzen","year":"2024","journal-title":"J Clin Oncol"},{"issue":"4","key":"10.1016\/j.ctrv.2024.102752_b0230","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1016\/S1473-3099(10)70065-7","article-title":"Systematic reviews: CRD\u2019s guidance for undertaking reviews in health care","volume":"10","author":"Tacconelli","year":"2010","journal-title":"Lancet Infect Dis"},{"issue":"16_suppl","key":"10.1016\/j.ctrv.2024.102752_b0235","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2022.40.16_suppl.3511","article-title":"Neoadjuvant nivolumab, ipilimumab, and celecoxib in MMR-proficient and MMR-deficient colon cancers: Final clinical analysis of the NICHE study","volume":"40","author":"Verschoor","year":"2022","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2024.102752_b0240","doi-asserted-by":"crossref","DOI":"10.1016\/j.annonc.2022.08.016","article-title":"LBA7 Neoadjuvant immune checkpoint inhibition in locally advanced MMR-deficient colon cancer: The NICHE-2 study","volume":"33","author":"Chalabi","year":"2022","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ctrv.2024.102752_b0245","doi-asserted-by":"crossref","DOI":"10.1016\/j.annonc.2023.10.023","article-title":"LBA31 Neoadjuvant nivolumab plus relatlimab (anti-LAG3) in locally advanced MMR-deficient colon cancers: The NICHE-3 study","volume":"34","author":"Verschoor","year":"2023","journal-title":"Ann Oncol"},{"issue":"1","key":"10.1016\/j.ctrv.2024.102752_b0250","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/S2468-1253(21)00348-4","article-title":"Neoadjuvant PD-1 blockade with toripalimab, with or without celecoxib, in mismatch repair-deficient or microsatellite instability-high, locally advanced, colorectal cancer (PICC): a single-centre, parallel-group, non-comparative, randomised, phase 2 trial","volume":"7","author":"Hu","year":"2022","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"25","key":"10.1016\/j.ctrv.2024.102752_b0255","doi-asserted-by":"crossref","first-page":"2363","DOI":"10.1056\/NEJMoa2201445","article-title":"PD-1 blockade in mismatch repair-deficient, locally advanced rectal cancer","volume":"386","author":"Cercek","year":"2022","journal-title":"N Engl J Med"},{"issue":"5","key":"10.1016\/j.ctrv.2024.102752_b0260","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1016\/S2468-1253(22)00439-3","article-title":"Neoadjuvant PD-1 blockade with sintilimab in mismatch-repair deficient, locally advanced rectal cancer: an open-label, single-centre phase 2 study","volume":"8","author":"Chen","year":"2023","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"2","key":"10.1016\/j.ctrv.2024.102752_b0265","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1200\/JCO.22.00686","article-title":"Neoadjuvant nivolumab plus ipilimumab and adjuvant nivolumab in localized deficient mismatch repair\/microsatellite instability-high gastric or esophagogasric junction adenocarcinoma: The GERCOR NEONIPIGA phase II study","volume":"41","author":"Andr\u00e9","year":"2023","journal-title":"J Clin Oncol"},{"issue":"4_suppl","key":"10.1016\/j.ctrv.2024.102752_b0270","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2023.41.4_suppl.358","article-title":"INFINITY: A multicentre, single-arm, multi-cohort, phase II trial of tremelimumab and durvalumab as neoadjuvant treatment of patients with microsatellite instability-high (MSI) resectable gastric or gastroesophageal junction adenocarcinoma (GAC\/GEJAC)","volume":"41","author":"Pietrantonio","year":"2023","journal-title":"J Clin Oncol"},{"issue":"12","key":"10.1016\/j.ctrv.2024.102752_b0275","doi-asserted-by":"crossref","first-page":"2181","DOI":"10.1200\/JCO.22.01351","article-title":"Neoadjuvant pembrolizumab in localized microsatellite instability high\/deficient mismatch repair solid tumors","volume":"41","author":"Ludford","year":"2023","journal-title":"J Clin Oncol"},{"issue":"3_suppl","key":"10.1016\/j.ctrv.2024.102752_b0280","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2024.42.3_suppl.117","article-title":"Neoadjuvant botensilimab plus balstilimab in resectable mismatch repair proficient and deficient colorectal cancer: NEST-1 clinical trial","volume":"42","author":"Kasi","year":"2024","journal-title":"J Clin Oncol"},{"issue":"4","key":"10.1016\/j.ctrv.2024.102752_b0285","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1038\/s41591-020-0805-8","article-title":"Neoadjuvant immunotherapy leads to pathological responses in MMR-proficient and MMR-deficient early-stage colon cancers","volume":"26","author":"Chalabi","year":"2020","journal-title":"Nat Med"},{"key":"10.1016\/j.ctrv.2024.102752_b0290","article-title":"PD-1 blockade as curative intent therapy in mismatch repair deficient locally advanced rectal cancer","author":"Cercek","year":"2023","journal-title":"JSMO Annual Meeting"},{"issue":"23","key":"10.1016\/j.ctrv.2024.102752_b0295","doi-asserted-by":"crossref","first-page":"2207","DOI":"10.1056\/NEJMoa2017699","article-title":"Pembrolizumab in microsatellite-instability\u2013high advanced colorectal cancer","volume":"383","author":"Andr\u00e9","year":"2020","journal-title":"N Engl J Med"},{"issue":"35","key":"10.1016\/j.ctrv.2024.102752_b0300","doi-asserted-by":"crossref","first-page":"4176","DOI":"10.1200\/JCO.2015.63.4238","article-title":"Adjuvant fluorouracil, leucovorin, and oxaliplatin in stage II to III colon cancer: updated 10-year survival and outcomes according to BRAF mutation and mismatch repair status of the MOSAIC Study","volume":"33","author":"Andr\u00e9","year":"2015","journal-title":"J Clin Oncol"},{"issue":"2","key":"10.1016\/j.ctrv.2024.102752_b0305","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1093\/jnci\/djaa052","article-title":"Pathological tumor response following immune checkpoint blockade for deficient mismatch repair advanced colorectal cancer","volume":"113","author":"Ludford","year":"2021","journal-title":"JNCI J Natl Cancer Inst"},{"key":"10.1016\/j.ctrv.2024.102752_b0310","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/j.ejca.2022.06.060","article-title":"Colon cancer CT staging according to mismatch repair status: Comparison and suggestion of imaging features for high-risk colon cancer","volume":"174","author":"Hong","year":"2022","journal-title":"Eur J Cancer"},{"issue":"1","key":"10.1016\/j.ctrv.2024.102752_b0315","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1097\/SLA.0000000000002447","article-title":"Organ preservation in cT2N0 rectal cancer after neoadjuvant chemoradiation therapy: the impact of radiation therapy dose-escalation and consolidation chemotherapy","volume":"269","author":"Habr-Gama","year":"2019","journal-title":"Ann Surg"},{"issue":"5","key":"10.1016\/j.ctrv.2024.102752_b0320","doi-asserted-by":"crossref","first-page":"984","DOI":"10.2214\/AJR.15.15785","article-title":"Diagnostic accuracy of CT for local staging of colon cancer: A systematic review and meta-analysis","volume":"207","author":"Nerad","year":"2016","journal-title":"Am J Roentgenol"},{"issue":"24","key":"10.1016\/j.ctrv.2024.102752_b0325","doi-asserted-by":"crossref","first-page":"2261","DOI":"10.1056\/NEJMoa2200075","article-title":"Circulating tumor DNA analysis guiding adjuvant therapy in stage II colon cancer","volume":"386","author":"Tie","year":"2022","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.ctrv.2024.102752_b0330","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1038\/s41591-022-02115-4","article-title":"Molecular residual disease and efficacy of adjuvant chemotherapy in patients with colorectal cancer","volume":"29","author":"Kotani","year":"2023","journal-title":"Nat Med"},{"issue":"1","key":"10.1016\/j.ctrv.2024.102752_b0335","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1038\/s41571-020-0403-1","article-title":"TGF\u03b2 biology in cancer progression and immunotherapy","volume":"18","author":"Derynck","year":"2021","journal-title":"Nat Rev Clin Oncol"},{"issue":"8","key":"10.1016\/j.ctrv.2024.102752_b0340","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1016\/j.annonc.2023.05.010","article-title":"Prediction of response to immune checkpoint blockade in patients with metastatic colorectal cancer with microsatellite instability","volume":"34","author":"Ratovomanana","year":"2023","journal-title":"Ann Oncol"},{"issue":"12","key":"10.1016\/j.ctrv.2024.102752_b0345","doi-asserted-by":"crossref","first-page":"1168","DOI":"10.1056\/NEJMc2031965","article-title":"The spectrum of benefit from checkpoint blockade in hypermutated tumors","volume":"384","author":"Rousseau","year":"2021","journal-title":"N Engl J Med"},{"issue":"8","key":"10.1016\/j.ctrv.2024.102752_b0350","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1007\/s11912-021-01085-z","article-title":"Immunology of lynch syndrome","volume":"23","author":"Pastor","year":"2021","journal-title":"Curr Oncol Rep"},{"key":"10.1016\/j.ctrv.2024.102752_b0355","unstructured":"Gupta et al, NCCN Guidelines Version 2.2023 Genetic\/Familial High-Risk Assessment: Colorectal - October 30, 2023. Accessed January 21, 2024."},{"issue":"7","key":"10.1016\/j.ctrv.2024.102752_b0360","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1007\/s00262-015-1771-8","article-title":"Immune-modulating properties of ionizing radiation: rationale for the treatment of cancer by combination radiotherapy and immune checkpoint inhibitors","volume":"65","author":"Derer","year":"2016","journal-title":"Cancer Immunol Immunother"},{"issue":"5","key":"10.1016\/j.ctrv.2024.102752_b0365","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1038\/nrclinonc.2018.9","article-title":"Improving immunotherapy outcomes with anti-angiogenic treatments and vice versa","volume":"15","author":"Khan","year":"2018","journal-title":"Nat Rev Clin Oncol"},{"issue":"7","key":"10.1016\/j.ctrv.2024.102752_b0370","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1016\/S1470-2045(22)00274-1","article-title":"Upfront FOLFOXIRI plus bevacizumab with or without atezolizumab in the treatment of patients with metastatic colorectal cancer (AtezoTRIBE): a multicentre, open-label, randomised, controlled, phase 2 trial","volume":"23","author":"Antoniotti","year":"2022","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ctrv.2024.102752_b0375","doi-asserted-by":"crossref","DOI":"10.1016\/j.neo.2022.100867","article-title":"Synergizing radiotherapy and immunotherapy: Current challenges and strategies for optimization","volume":"36","author":"Rajeev-Kumar","year":"2023","journal-title":"Neoplasia"},{"key":"10.1016\/j.ctrv.2024.102752_b0380","doi-asserted-by":"crossref","first-page":"S230","DOI":"10.1016\/j.annonc.2020.04.052","article-title":"SO-37 Short-term results of VOLTAGE-A: Nivolumab monotherapy and subsequent radical surgery following preoperative chemoradiotherapy in patients with microsatellite stability and microsatellite instability-high, locally advanced rectal cancer (EPOC 1504)","volume":"31","author":"Yuki","year":"2020","journal-title":"Ann Oncol"},{"issue":"11","key":"10.1016\/j.ctrv.2024.102752_b0385","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2021-003554","article-title":"Phase II, single-arm trial of preoperative short-course radiotherapy followed by chemotherapy and camrelizumab in locally advanced rectal cancer","volume":"9","author":"Lin","year":"2021","journal-title":"J Immunother Cancer"},{"issue":"6","key":"10.1016\/j.ctrv.2024.102752_b0390","doi-asserted-by":"crossref","first-page":"1136","DOI":"10.1158\/1078-0432.CCR-21-3213","article-title":"Preoperative chemoradiotherapy plus nivolumab before surgery in patients with microsatellite stable and microsatellite instability-high locally advanced rectal cancer","volume":"28","author":"Bando","year":"2022","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ctrv.2024.102752_b0395","doi-asserted-by":"crossref","first-page":"S1266","DOI":"10.1016\/j.annonc.2023.10.017","article-title":"LBA25 Neoadjuvant short-course radiotherapy followed by camrelizumab plus chemotherapy versus long-course chemoradiotherapy followed by chemotherapy in locally advanced rectal cancer: A randomized phase III trial (UNION)","volume":"34","author":"Zhang","year":"2023","journal-title":"Ann Oncol"},{"issue":"4","key":"10.1016\/j.ctrv.2024.102752_b0400","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1016\/S1470-2045(20)30737-3","article-title":"Avelumab plus standard-of-care chemoradiotherapy versus chemoradiotherapy alone in patients with locally advanced squamous cell carcinoma of the head and neck: a randomised, double-blind, placebo-controlled, multicentre, phase 3 trial","volume":"22","author":"Lee","year":"2021","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ctrv.2024.102752_b0405","doi-asserted-by":"crossref","DOI":"10.1016\/j.ctrv.2023.102676","article-title":"Neoadjuvant chemotherapy for early-stage colon cancer","volume":"123","author":"Audisio","year":"2024","journal-title":"Cancer Treat Rev"},{"issue":"3","key":"10.1016\/j.ctrv.2024.102752_b0410","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1111\/codi.16450","article-title":"Incorporating neoadjuvant chemotherapy into locally advanced colon cancer treatment pathways: Real-life experience of implementing FOxTROT","volume":"25","author":"Williams","year":"2023","journal-title":"Colorectal Dis"},{"key":"10.1016\/j.ctrv.2024.102752_b0415","doi-asserted-by":"crossref","unstructured":"on behalf of the Rectal Cancer Consortium, Smith JJ, Chow OS, Gollub MJ, Nash GM, Temple LK, et al. Organ Preservation in Rectal Adenocarcinoma: a phase II randomized controlled trial evaluating 3-year disease-free survival in patients with locally advanced rectal cancer treated with chemoradiation plus induction or consolidation chemotherapy, and total mesorectal excision or nonoperative management. BMC Cancer. 2015 Dec;15(1):767.","DOI":"10.1186\/s12885-015-1632-z"},{"issue":"2","key":"10.1016\/j.ctrv.2024.102752_b0420","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1016\/S1470-2045(15)00467-2","article-title":"Watch-and-wait approach versus surgical resection after chemoradiotherapy for patients with rectal cancer (the OnCoRe project): a propensity-score matched cohort analysis","volume":"17","author":"Renehan","year":"2016","journal-title":"Lancet Oncol"},{"issue":"12","key":"10.1016\/j.ctrv.2024.102752_b0425","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1016\/S2468-1253(18)30301-7","article-title":"Factors affecting local regrowth after watch and wait for patients with a clinical complete response following chemoradiotherapy in rectal cancer (InterCoRe consortium): an individual participant data meta-analysis","volume":"3","author":"Chadi","year":"2018","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"4","key":"10.1016\/j.ctrv.2024.102752_b0430","doi-asserted-by":"crossref","first-page":"e185896","DOI":"10.1001\/jamaoncol.2018.5896","article-title":"Assessment of a watch-and-wait strategy for rectal cancer in patients with a complete response after neoadjuvant therapy","volume":"5","author":"Smith","year":"2019","journal-title":"JAMA Oncol"},{"issue":"16_suppl","key":"10.1016\/j.ctrv.2024.102752_b0435","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2023.41.16_suppl.3520","article-title":"Sustained organ preservation in patients with rectal cancer treated with total neoadjuvant therapy: Long-term results of the OPRA trial","volume":"41","author":"Verheij","year":"2023","journal-title":"J Clin Oncol"},{"issue":"7","key":"10.1016\/j.ctrv.2024.102752_b0440","doi-asserted-by":"crossref","first-page":"1785","DOI":"10.1111\/codi.15636","article-title":"The evaluation of follow-up strategies of watch-and-wait patients with a complete response after neoadjuvant therapy in rectal cancer","volume":"23","author":"Haak","year":"2021","journal-title":"Colorectal Dis"},{"key":"10.1016\/j.ctrv.2024.102752_b0445","doi-asserted-by":"crossref","unstructured":"on behalf of the SANO-study group, Eyck BM, Van Der Wilk BJ, Noordman BJ, Wijnhoven BPL, Lagarde SM, et al. Updated protocol of the SANO trial: a stepped-wedge cluster randomised trial comparing surgery with active surveillance after neoadjuvant chemoradiotherapy for oesophageal cancer. Trials. 2021 Dec;22(1):345.","DOI":"10.1186\/s13063-021-05274-w"},{"issue":"11","key":"10.1016\/j.ctrv.2024.102752_b0450","doi-asserted-by":"crossref","first-page":"1894","DOI":"10.1002\/ijc.34647","article-title":"China special issue on gastrointestinal tumors-Radiological features of pathological complete response in mismatch repair deficient colorectal cancer after neoadjuvant PD -1 blockade: A post hoc analysis of the PICC phase II trial","volume":"153","author":"Cao","year":"2023","journal-title":"Int J Cancer"},{"issue":"7517","key":"10.1016\/j.ctrv.2024.102752_b0455","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1038\/nature13480","article-title":"Comprehensive molecular characterization of gastric adenocarcinoma","volume":"513","author":"The Cancer Genome Atlas Research Network","year":"2014","journal-title":"Nature"},{"issue":"5","key":"10.1016\/j.ctrv.2024.102752_b0460","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1097\/SLA.0000000000004341","article-title":"Incidence and grading of complications after gastrectomy for cancer using the GASTRODATA Registry: A European Retrospective Observational Study","volume":"272","author":"Baiocchi","year":"2020","journal-title":"Ann Surg"},{"issue":"5","key":"10.1016\/j.ctrv.2024.102752_b0465","doi-asserted-by":"crossref","first-page":"960","DOI":"10.1016\/j.ejso.2020.11.136","article-title":"Functional outcomes of surgery for colon cancer: A systematic review and meta-analysis","volume":"47","author":"Verkuijl","year":"2021","journal-title":"Eur J Surg Oncol"},{"issue":"1","key":"10.1016\/j.ctrv.2024.102752_b0470","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1186\/s12877-017-0569-2","article-title":"The impact of frailty and sarcopenia on postoperative outcomes in older patients undergoing gastrectomy surgery: a systematic review and meta-analysis","volume":"17","author":"Shen","year":"2017","journal-title":"BMC Geriatr"},{"key":"10.1016\/j.ctrv.2024.102752_b0475","doi-asserted-by":"crossref","DOI":"10.1016\/j.ctrv.2020.101980","article-title":"Challenges in the treatment of gastric cancer in the older patient","volume":"85","author":"Joharatnam-Hogan","year":"2020","journal-title":"Cancer Treat Rev"},{"issue":"7","key":"10.1016\/j.ctrv.2024.102752_b0480","doi-asserted-by":"crossref","first-page":"969","DOI":"10.1093\/jnci\/djac071","article-title":"Quality of life in older adults after major cancer surgery: the GOSAFE international study","volume":"114","author":"Montroni","year":"2022","journal-title":"JNCI J Natl Cancer Inst"},{"key":"10.1016\/j.ctrv.2024.102752_b0485","doi-asserted-by":"crossref","DOI":"10.1016\/j.annonc.2023.04.275","article-title":"P-219 Non-operative management of localized mismatch repair deficient colon cancer: A real-world perspective","volume":"34","author":"Chakrabarti","year":"2023","journal-title":"Ann Oncol"},{"issue":"14","key":"10.1016\/j.ctrv.2024.102752_b0490","article-title":"Locally advanced rectal cancer with dMMR\/MSI-H may be excused from surgery after neoadjuvant anti-PD-1 monotherapy: a multiple-center, cohort study","volume":"27","author":"Yang","year":"2023","journal-title":"Front Immunol"},{"issue":"10","key":"10.1016\/j.ctrv.2024.102752_b0495","doi-asserted-by":"crossref","first-page":"e996","DOI":"10.1097\/DCR.0000000000002466","article-title":"Neoadjuvant immune checkpoint inhibition improves organ preservation in T4bM0 colorectal cancer with mismatch repair deficiency: A retrospective observational study","volume":"66","author":"Han","year":"2023","journal-title":"Dis Colon Rectum"},{"issue":"13","key":"10.1016\/j.ctrv.2024.102752_b0500","article-title":"Efficacy and safety of neoadjuvant monoimmunotherapy with PD-1 inhibitor for dMMR\/MSI\u2043H locally advanced colorectal cancer: A single-center real-world study","volume":"25","author":"Zhang","year":"2022","journal-title":"Front Immunol"},{"issue":"3","key":"10.1016\/j.ctrv.2024.102752_b0505","doi-asserted-by":"crossref","first-page":"1894","DOI":"10.1245\/s10434-021-10576-z","article-title":"Cost effectiveness of watch and wait versus resection in rectal cancer patients with complete clinical response to neoadjuvant chemoradiation","volume":"29","author":"Cui","year":"2022","journal-title":"Ann Surg Oncol"},{"issue":"2","key":"10.1016\/j.ctrv.2024.102752_b0510","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1016\/j.clon.2022.10.002","article-title":"The cost-effectiveness of watch and wait for rectal cancer","volume":"35","author":"Bibi","year":"2023","journal-title":"Clin Oncol"},{"issue":"Suppl_1","key":"10.1016\/j.ctrv.2024.102752_b0515","article-title":"FA03.06: the cost benefit of a watch and wait policy for complete clinical responders following neo-adjuvant therapy in esophageal cancer","volume":"31","author":"Abdelatif","year":"2018","journal-title":"Dis Esophagus"},{"issue":"10","key":"10.1016\/j.ctrv.2024.102752_b0520","doi-asserted-by":"crossref","first-page":"e741","DOI":"10.1016\/j.crad.2023.06.012","article-title":"CT-based radiomics nomogram for the preoperative prediction of microsatellite instability and clinical outcomes in colorectal cancer: a multicentre study","volume":"78","author":"Li","year":"2023","journal-title":"Clin Radiol"},{"issue":"1","key":"10.1016\/j.ctrv.2024.102752_b0525","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1016\/j.annonc.2021.10.213","article-title":"89Zr-pembrolizumab imaging as a non-invasive approach to assess clinical response to PD-1 blockade in cancer","volume":"33","author":"Kok","year":"2022","journal-title":"Ann Oncol"},{"issue":"12","key":"10.1016\/j.ctrv.2024.102752_b0530","doi-asserted-by":"crossref","first-page":"1852","DOI":"10.1038\/s41591-018-0255-8","article-title":"89Zr-atezolizumab imaging as a non-invasive approach to assess clinical response to PD-L1 blockade in cancer","volume":"24","author":"Bensch","year":"2018","journal-title":"Nat Med"},{"key":"10.1016\/j.ctrv.2024.102752_b0535","doi-asserted-by":"crossref","unstructured":"Farwell MD, Gamache RF, Babazada H, Hellmann MD, Harding JJ, Korn R, et al. CD8-targeted PET Imaging of Tumor Infiltrating T cells in Patients with Cancer: A Phase I First-in-Human Study of 89 Zr-Df-IAB22M2C, a Radiolabeled anti-CD8 Minibody. J Nucl Med. 2021 Aug 19;jnumed.121.262485.","DOI":"10.2967\/jnumed.121.262485"},{"issue":"3","key":"10.1016\/j.ctrv.2024.102752_b0540","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1016\/j.ijrobp.2019.10.046","article-title":"Long-term patient-reported outcomes after high-dose chemoradiation therapy for nonsurgical management of distal rectal cancer","volume":"106","author":"Dizdarevic","year":"2020","journal-title":"Int J Radiat Oncol"}],"container-title":["Cancer Treatment Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S030573722400080X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S030573722400080X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,10,16]],"date-time":"2024-10-16T15:57:16Z","timestamp":1729094236000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S030573722400080X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7]]},"references-count":108,"alternative-id":["S030573722400080X"],"URL":"https:\/\/doi.org\/10.1016\/j.ctrv.2024.102752","relation":{},"ISSN":["0305-7372"],"issn-type":[{"value":"0305-7372","type":"print"}],"subject":[],"published":{"date-parts":[[2024,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Non-operative management after immune checkpoint inhibitors for early-stage, dMMR\/MSI-H gastrointestinal cancers","name":"articletitle","label":"Article Title"},{"value":"Cancer Treatment Reviews","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ctrv.2024.102752","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"102752"}}